Metagenomi to Present New Data for Its Novel Gene-Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, announced it will present new data during the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting in Los Angeles (May 16 – 20).
“As we advance the field of genetic medicines, we need to develop novel gene editing systems that allow us to address and correct the underlying disease-causing genes with precision and efficiency. The data we will present at ASGCT demonstrates the ability of our metagenomics-powered discovery platform in rapidly identifying new gene editing tools with unique characteristics for therapeutic application,” said Sarah Noonberg, MD, PhD, Chief Medical Officer of Metagenomi. “We look forward to showcasing several gene editing approaches, including updates on our large integration capabilities, novel base editing systems, and enhanced editing efficiencies of a lead Type V nuclease validated through nonhuman primate studies.”
Metagenomi Presentations at ASGCT
A Novel Type V CRISPR System with Potent Editing Activity in Mice and Non-Human Primates (Abstract #229)
- Oral Presentation (Virtual) – Thursday, May 18, 4:00 p.m. – 4:15 p.m. PT
- Presented by Alan R. Brooks, PhD, Senior Vice President of Preclinical Research
A Metagenomics-Derived Gene-Editing Toolbox Enables Efficient Genome Engineering with Nucleases and Base-Editors in Primary Cells and In Vivo (Abstract #256)
- Oral Presentation – Friday, May 19, 3:45 p.m. – 4:00 p.m. PT
- Presented by Gregory J. Cost, PhD, Vice President of Biology
Targeted Integration to Endogenous Sites in the Human Genome Using CRISPR-Associated Transposases Discovered from Natural Environments (Abstract #1429)
- Poster Presentation – Friday, May 19, 12 p.m. PT
- Presented by Jason Liu, PhD, Sr. Scientist
Full abstracts are available on the ASGCT meeting website.
About Metagenomi
Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co.